Mark Erlander
CEO
CEO
Executive compensation
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Cardiff Oncology, Inc. (CRDF) | CEO | $635,000 | $3,023,344 |
| 2024 | Cardiff Oncology, Inc. (CRDF) | CEO | $610,584 | $2,401,376 |
| 2023 | Cardiff Oncology, Inc. (CRDF) | CEO | $594,400 | $1,547,772 |
| 2022 | Cardiff Oncology, Inc. (CRDF) | CEO | $570,600 | $1,590,347 |
| 2021 | Cardiff Oncology, Inc. (CRDF) | CEO | $532,716 | $3,635,198 |
| 2020 | Cardiff Oncology, Inc. (CRDF) | CEO | $444,764 | $1,150,703 |
| 2019 | Cardiff Oncology, Inc. (CRDF) | CSO | $398,729 | $852,951 |
| 2018 | Cardiff Oncology, Inc. (CRDF) | CSO | $387,155 | $908,524 |
Executive changes
Earnings-call appearances
-
Cardiff Oncology, Inc. Q4 FY2024 Earnings Call2025-02-27
Cardiff Oncology, Inc. (CRDF)
-
Cardiff Oncology, Inc. Q2 FY2024 Earnings Call2024-08-08
Cardiff Oncology, Inc. (CRDF)
-
Cardiff Oncology, Inc. Q1 FY2024 Earnings Call2024-05-02
Cardiff Oncology, Inc. (CRDF)
-
Cardiff Oncology, Inc. Q4 FY2023 Earnings Call2024-02-29
Cardiff Oncology, Inc. (CRDF)
-
Cardiff Oncology, Inc. Q3 FY2023 Earnings Call2023-11-02
Cardiff Oncology, Inc. (CRDF)